Drug-coated balloons (DCBs) are a novel treatment strategy for coronary artery disease based on the fast and homogenous transfer of antiproliferative drugs into the vessel wall during single balloon inflation by means of a lipophilic matrix without the use of permanent implants (Figure 1).

2020年5月27日 · Patient-level data from 10 randomized trials comparing DCB angioplasty to repeat drug-eluting stent (DES) implantation in the treatment of coronary ISR (710 patients with BMS [bare-metal stent]-ISR and 1,248 with DES-ISR) were included in this analysis. The primary efficacy endpoint was target lesion revascularization (TLR) at 3 years.

2025年2月1日 · Importance: Drug-coated balloon (DCB) angioplasty has emerged as an alternative to drug-eluting stent (DES) implantation for percutaneous coronary intervention (PCI) in patients with coronary in-stent restenosis (ISR) as well as de novo coronary artery disease.

Drug-coated balloon (DCB) technology was developed to deliver the antiproliferative drugs to the vessel wall without leaving any permanent prosthesis or durable polymers. The absence of foreign material can reduce the risk of very late stent ...

2024年9月14日 · Drug-coated balloon (DCB) angioplasty is a novel approach for the treatment of coronary artery disease. 4 Following adequate lesion preparation, the expansion of a DCB can rapidly deliver antiproliferative drugs into the arterial wall through a lipophilic matrix, avoiding the need to implant a permanent scaffold and thereby minimising the ...

3 天之前 · Purpose of Review The purpose of this work is to review the role of drug-coated balloons (DCBs) in contemporary coronary artery disease (CAD) management by focusing on its clinical indications and technical considerations, supported by updated insights from the International DCB Consensus Group. Recent Findings While percutaneous coronary intervention (PCI) and drug-eluting stents were ...

2020年6月22日 · Drug-coated balloons (DCBs) are a novel treatment strategy for coronary artery disease based on the fast and homogenous transfer of antiproliferative drugs into the vessel wall during single balloon inflation by means of a lipophilic matrix without the use of permanent implants (Figure 1).

Non-stent-based local drug delivery by a drug-coated balloon (DCB) has been investigated, as it leaves no metallic mesh. A DCB consists of a semicompliant balloon coated with antiproliferative agents encapsulated in a polymer matrix, which is released into …

Drug coated balloons (DCBs) are currently indicated in guidelines as a first choice option in the management of instant restenosis, whereas their use in de novo lesions is still debated.

every PCI should aim at using the DCB-only strategy, which implies a similar approach for every lesion preparation. This requires an optimal angioplasty result, which may be assessed using angiography, physiology, or intravascular imaging, with drug delivery then performed with a DCB. Stent implanta-tion may be performed for suboptimal results

5 天之前 · A total of 230 patients were randomised to the sirolimus DCB or the paclitaxel DCB group in a 1:1 ratio. Angiographic and clinical follow-ups were planned at 9 months and 1 year, respectively. The primary endpoint was diameter stenosis (DS) in the SB at 9 months.

2016年7月26日 · Historically, in-stent restenosis represents the first clinical application of DCB in coronary arteries and is where its most robust scientific evidence is found. In 2006, the first human trial involving DCB demonstrated the superiority of DCB over plain balloon angioplasty in terms of in-segment late lumen loss for the treatment of BMS restenosis.

In this multicenter, randomized controlled trial, patients with true coronary bifurcations who had side branch diameter stenosis of ≥70% after main vessel stenting at 22 centers in China, Indonesia, Italy, and Korea were randomly assigned to either DCB or NCB intervention.

2025年3月13日 · The UH Harrington Heart & Vascular Institute is launching a robust scientific program of five upcoming industry-sponsored DCB trials, with plans to submit them for IRB approval in the coming months. “Three of the studies will test some of these technologies in the SV disease setting, and two in the ISR one,” Dr. Cortese says.

Therefore, we aimed to evaluate angiographic and clinical outcomes of the two most effective treatments DES vs. drug-eluting balloon (DCB) for patients with DES-ISR. Methods: This meta-analysis used the data from the randomized controlled trials (RCTs), which were identified by a systematic search in the databases of PubMed, Embase, and ...

4 天之前 · This study analyzed 317 patients who underwent DCB-based intervention for de novo CAD and angiographic follow-up: SR (successful, stent-like result: diameter stenosis < 20% at follow-up ...

2 天之前 · Background Drug-coated balloon (DCB) are effective treatment options for patients with coronary artery disease and using of scoring or cutting balloon before the DCB usage were recommended. ... After nitroglycerin and heparin injections, angiography and balloon injury of bilateral iliac arteries were performed using a 3.0 x 20 mm noncompliant ...

2025年3月15日 · Consecutive patients with de novo coronary artery disease who underwent PCI with intention-to-treat DCB angioplasty, with or without stent implantation, were retrospectively enrolled between 2018 and 2022 at 2 Italian centers.

Drug-coated balloon (DCB) angioplasty has emerged as a promising option. Devoid of a metallic scaffold, it may mitigate many of the risks of stent-related complications. Herein we present our experience of DCB angioplasty for de novo CAD in a single West Australian centre.

2021年7月21日 · Currently the two methods to ensure successful DCB treatment of a stenotic lesion are angiography or physiology-guided DCB application. This review will evaluate these two methods based on previous evidence and make suggestions on how to perform DCB treatment more efficiently and safely.